Dual down‐regulation of EGFR and ErbB2 by berberine contributes to suppression of migration and invasion of human ovarian cancer cells

The overexpression of EGFR and/or ErbB2 occurs frequently in ovarian cancers and is associated with poor prognosis. The purpose of this study was to examine the anticancer effects and molecular mechanisms of berberine on human ovarian cancer cells with different levels of EGFR and/or ErbB2. We found that berberine reduced the motility and invasiveness of ovarian cancer cells. Berberine depleted both EGFR and ErbB2 in ovarian cancer cells. Furthermore, berberine suppressed the activation of the EGFR and ErbB2 downstream targets cyclin D1, MMPs, and VEGF by down‐regulating the EGFR‐ErbB2/PI3K/Akt signaling pathway. The berberine‐mediated inhibition of MMP‐2 and MMP‐9 activity could be rescued by co‐treatment with EGF. Finally, we demonstrated that berberine induced ErbB2 depletion through ubiquitin‐mediated proteasome degradation. In conclusion, the suppressive effects of berberine on the ovarian cancer cells that differ in the expression of EGFR and ErbB2 may be mediated by the dual depletion of EGFR and/or ErbB2.

[1]  I. Meinhold-Heerlein,et al.  Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials , 2019, Cancers.

[2]  S. Tolaney,et al.  HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance , 2019, Therapeutic advances in medical oncology.

[3]  P. Ismail,et al.  Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study , 2019, Pharmacological reports : PR.

[4]  Jin Wang,et al.  Coptidis Rhizoma: a comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology , 2019, Pharmaceutical biology.

[5]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[6]  Shulan Zhang,et al.  Berberine suppresses growth and metastasis of endometrial cancer cells via miR-101/COX-2. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  P. Ismail,et al.  Molecular modeling, dynamics simulations, and binding efficiency of berberine derivatives: A new group of RAF inhibitors for cancer treatment , 2018, PloS one.

[8]  Jeong Eon Lee,et al.  Berberine Suppresses Fibronectin Expression through Inhibition of c-Jun Phosphorylation in Breast Cancer Cells , 2018, Journal of breast cancer.

[9]  Sicen Wang,et al.  The promotion function of Berberine for osteogenic differentiation of human periodontal ligament stem cells via ERK-FOS pathway mediated by EGFR , 2018, Scientific Reports.

[10]  Sangmin Kim,et al.  Berberine Suppresses Cell Motility Through Downregulation of TGF-β1 in Triple Negative Breast Cancer Cells , 2018, Cellular Physiology and Biochemistry.

[11]  Zhaojian Liu,et al.  Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition , 2017, Cell Death and Disease.

[12]  Yongjian Duan,et al.  Berberine and cinnamaldehyde together prevent lung carcinogenesis , 2017, Oncotarget.

[13]  Shijie Cao,et al.  The metabolism of berberine and its contribution to the pharmacological effects , 2017, Drug metabolism reviews.

[14]  M. Ye,et al.  FM807, a curcumin analogue, shows potent antitumor effects in nasopharyngeal carcinoma cells by heat shock protein 90 inhibition , 2017, Oncotarget.

[15]  Feng Jiang,et al.  Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer , 2016, International journal of molecular sciences.

[16]  Shuo Yang,et al.  Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer , 2016, Oncotarget.

[17]  J. Izbicki,et al.  In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines. , 2016, International journal of molecular medicine.

[18]  Zhaojian Liu,et al.  Berberine Induces Senescence of Human Glioblastoma Cells by Downregulating the EGFR–MEK–ERK Signaling Pathway , 2014, Molecular Cancer Therapeutics.

[19]  P. Ismail,et al.  Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer. , 2014, European journal of pharmacology.

[20]  R. Peek,et al.  Berberine Inhibits Proliferation and Down-Regulates Epidermal Growth Factor Receptor through Activation of Cbl in Colon Tumor Cells , 2013, PloS one.

[21]  Jah-yao Liu,et al.  Berberine, an isoquinoline alkaloid, inhibits the metastatic potential of breast cancer cells via Akt pathway modulation. , 2012, Journal of agricultural and food chemistry.

[22]  R. Nahta.  Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. , 2012, Current medicinal chemistry.

[23]  S. Hsu,et al.  Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells. , 2011, Cancer Letters.

[24]  Zhe-Sheng Chen,et al.  Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu. , 2011, Molecular pharmaceutics.

[25]  Jah-yao Liu,et al.  Growth suppression of HER2-overexpressing breast cancer cells by berberine via modulation of the HER2/PI3K/Akt signaling pathway. , 2011, Journal of agricultural and food chemistry.

[26]  Hyung Gyun Kim,et al.  Suppression of EGF-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling. , 2011, Molecular nutrition & food research.

[27]  Q. Sheng,et al.  The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer , 2011, British Journal of Cancer.

[28]  G. Mills,et al.  Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges , 2009, Journal of oncology.

[29]  Xiuping Chen,et al.  A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs , 2009, Anti-cancer drugs.

[30]  Jah-yao Liu,et al.  Ganoderma tsugae extract inhibits expression of epidermal growth factor receptor and angiogenesis in human epidermoid carcinoma cells: In vitro and in vivo. , 2009, Cancer letters.

[31]  R. Bose,et al.  The ErbB kinase domain: structural perspectives into kinase activation and inhibition. , 2009, Experimental cell research.

[32]  Jeong Eon Lee,et al.  Berberine Suppresses TNF-α-induced MMP-9 and Cell Invasion through Inhibition of AP-1 Activity in MDA-MB-231 Human Breast Cancer Cells , 2008, Molecules.

[33]  A. Baron,et al.  Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. , 2008, Biochimica et biophysica acta.

[34]  Jen-kun Lin,et al.  Apigenin Induces Apoptosis through Proteasomal Degradation of HER2/neu in HER2/neu-overexpressing Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt-dependent Pathway* , 2004, Journal of Biological Chemistry.

[35]  J. Gustafsson,et al.  ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. , 2004, Gynecologic oncology.

[36]  N. Rosen,et al.  Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 , 2002, Oncogene.